Skip to main content
. 2018 Nov 29;8(4):79. doi: 10.3390/diagnostics8040079

Table 1.

Head and neck cancer patients (n = 29) demographics data.

Patient # Age HPV Status TNM Staging Site DNA (ng/mL) Sample Type
1 60–65 Positive T2N2b Oropharyngeal 41.6 Plasma
2 55–60 Positive T2N2bM0 Oropharyngeal 22.5 Plasma
3 55–60 Positive T3N1 Oropharyngeal 10.2 Plasma
4 65–70 Negative T3N1 Oropharyngeal 15.4 Plasma
5 60–65 Positive T3N1a Oropharyngeal 7.8 Plasma
6 45–50 Positive T3N2b Oropharyngeal 10.5 Plasma
7 70–75 Negative T3N2b Oropharyngeal 21.8 Plasma
8 55–60 Negative T3N2b Oropharyngeal 7.2 Plasma
9 60–65 Positive T3N2c Oropharyngeal 38.6 Plasma
10 60–65 Positive T3N2c Oropharyngeal 10.2 Plasma
11 65–70 Negative T3N2c Oral Cavity 4.5 Plasma
12 60–65 Positive T3N2c Oropharyngeal 29.2 Plasma
13 55–60 Positive T4aN2a Oropharyngeal 28.4 Plasma
14 60–65 Positive T4aN2b Hypopharyngeal 36.4 Plasma
15 60–65 Negative T4aN2b Oral Cavity 22.9 Plasma
16 55–60 Negative T4aN2b Oral Cavity 4.4 Plasma
17 60–65 Negative T4aN2b Oral Cavity 29.7 Plasma
18 60–65 Negative T4aN2c Laryngeal 10.3 Plasma
19 65–70 Positive T4N0 Oral Cavity 21.9 Plasma
20 45–50 Negative T4N0 Unknown 6.0 Plasma
21 65–70 Negative T4N0 Oral Cavity 27.1 Plasma
22 65–70 Positive T4N2b Oropharyngeal 20.1 Plasma
23 45–50 Positive T4N2b Oropharyngeal 32.4 Plasma
24 65–70 Negative T4N2b Oral Cavity 9.0 Plasma
25 50–55 Negative T4N2b Oropharyngeal 7.7 Plasma
26 35–40 Negative T4N2b Oral Cavity 12.0 Plasma
27 Unknown Positive T4N2c Unknown 7.3 Plasma
28 65–70 Negative T4N0 Oral Cavity 9.8 Plasma
29 60–65 Negative T4N0 Oral Cavity 8.5 Plasma

# Patient number; HPV: Human papillomavirus; TNM: Tumour-node-metastasis staging.